Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2012

Firms Combine Technologies to Optimize ChIP Studies

  • Rubicon Genomics and Diagenode agreed to integrate the former’s ThruPLEX® sample preparation technology into Diagenode’s epigentics platforms to improve DNA sample preparation for chromatin immunoprecipitation (ChIP) applications, in particular its new MicroPlex Library Preparation Kit for ChIP-seq studies.

    Diagenode develops instruments and reagent systems for life science applications, with a focus on epigenetics research and molecular diagnostics. The firm offers a range of kits for chromatin immunoprecipitation, and the SX-8G IP-Star® Compact Automated System for ChIP and DNA methylation analysis.

    Preanalytical sample preparation specialist Rubicon’s ThruPLEX-FD platform is a next-generation sequencing prep technology for the synthesis and amplification of ChIP DNA that uses a one-tube, three-step process. The firm says the technology can generate high-quality DNA from small samples, requires no intermediate purification steps, transfers, columns or gels, and can be used in plasma, FFPE, cDNA. Kits are available for sequencing on Illumina®, HiSeq®, MiSeq, and Genome Analyzer instrumentation. Development is ongoing for additional formats and platforms.

    “We are pleased to add the Rubicon ThruPLEX technology to Diagenode’s high-quality product line for ChIP studies,” comments Didier Allaer, Diagenode’s founder and CEO. “It’s fast, easy-to-use, and sensitive, producing high-quality results from challenging samples. We will also offer the MicroPLEX and True MicroChIP kits to our customers in conjunction with our new SX-8G IP-Star automated system, the first comprehensive system to automate ChIP and DNA methylation analysis.”



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »